| 000 | 05820cam a2200733Ia 4500 | ||
|---|---|---|---|
| 001 | ocn828933132 | ||
| 003 | OCoLC | ||
| 005 | 20220701010913.0 | ||
| 006 | m o d | ||
| 007 | cr cnu|||unuuu | ||
| 008 | 130305s2013 gw ob 001 0 eng d | ||
| 040 |
_aN$T _beng _epn _cN$T _dE7B _dDG1 _dCUS _dNOC _dOCLCO _dYDXCP _dOCLCA _dNLGGC _dOCLCF _dEBLCP _dUKMGB _dIDEBK _dDEBBG _dOCLCQ _dCOO _dNKT |
||
| 016 | 7 |
_a016300416 _2Uk |
|
| 019 |
_a829460534 _a961671411 _a962584608 |
||
| 020 |
_a9783527670420 _q(electronic bk.) |
||
| 020 |
_a3527670424 _q(electronic bk.) |
||
| 020 |
_a9783527670437 _q(electronic bk.) |
||
| 020 |
_a3527670432 _q(electronic bk.) |
||
| 020 | _z9783527324569 | ||
| 029 | 1 |
_aAU@ _b000051628906 |
|
| 029 | 1 |
_aAU@ _b000053032883 |
|
| 029 | 1 |
_aCHBIS _b010026927 |
|
| 029 | 1 |
_aCHVBK _b306231786 |
|
| 029 | 1 |
_aDEBBG _bBV041069692 |
|
| 029 | 1 |
_aDEBBG _bBV041911234 |
|
| 029 | 1 |
_aDKDLA _b820120-katalog:000655911 |
|
| 029 | 1 |
_aNLGGC _b372651682 |
|
| 029 | 1 |
_aNZ1 _b15340142 |
|
| 029 | 1 |
_aDEBBG _bBV043395562 |
|
| 035 |
_a(OCoLC)828933132 _z(OCoLC)829460534 _z(OCoLC)961671411 _z(OCoLC)962584608 |
||
| 050 | 4 | _aQR76.6 | |
| 072 | 7 |
_aNAT _x022000 _2bisacsh |
|
| 082 | 0 | 4 |
_a589.908734 _223 |
| 049 | _aMAIN | ||
| 245 | 0 | 0 |
_aMinicircle and Miniplasmid DNA Vectors : _bThe Future of Nonviral and Viral Gene Transfer / _cedited by Martin Schleef. |
| 260 |
_aWeinheim, Germany : _bWiley-Blackwell, _c©2013. |
||
| 300 | _a1 online resource (xxi, 235 pages) | ||
| 336 |
_atext _btxt _2rdacontent |
||
| 337 |
_acomputer _bc _2rdamedia |
||
| 338 |
_aonline resource _bcr _2rdacarrier |
||
| 504 | _aIncludes bibliographical references and index. | ||
| 588 | 0 | _aPrint version record. | |
| 505 | 0 | _aMinicircle and Miniplasmid DNA Vectors: The Future of Non-Viral and Viral Gene Transfer; Contents; List of Contributors; Perface; 1 Minicircle Patents: A Short IP Overview of Optimizing Nonviral DNA Vectors; 2 Operator-Repressor Titration: Stable Plasmid Maintenance without Selectable Marker Genes; 2.1 Introduction; 2.2 Antibiotics and Metabolic Burden; 2.3 The Mechanism of ORT; 2.4 ORT Strain Development; 2.5 ORT Miniplasmids; 2.6 DNA Vaccine and Gene Therapy Vectors; 2.7 ORT-VAC: Plasmid-Based Vaccine Delivery Using Salmonella enterica; 2.8 Recombinant Protein Expression. | |
| 505 | 8 | _a2.9 Conclusions and Future DevelopmentsReferences; 3 Selection by RNA-RNA Interaction: Maximally Minimized Antibiotic Resistance-Free Plasmids; 3.1 Gene Therapy and DNA Vaccines: Emerging Technologies; 3.1.1 Therapeutic Plasmids: General Design Principles; 3.2 Therapeutic Plasmids: Novel Design and the Problem of Selection; 3.2.1 Replication Control of ColE1-Type Plasmids as an Alternative Selection Marker; 3.2.2 The MINIback Concept: Selection by RNA-RNA Interaction; 3.2.3 Improved Production Processes by MINIback Plasmids; 3.2.4 Improving Sequence Composition; 3.2.5 Efficient Gene Transfer. | |
| 505 | 8 | _a3.3 ConclusionsAcknowledgments; References; 4 Plasmid-Based Medicinal Products -- Focus on pFAR: A Miniplasmid Free of Antibiotic Resistance Markers; 4.1 Introduction: Rationale for the Development of Biosafe DNA Plasmid Vectors; 4.2 Specific Requirements for the Use of DNA Product as Medicines; 4.2.1 Requirements for Plasmid Quality and Purity; 4.2.2 Requirements for the Removal of Antibiotic Resistance Markers from Plasmid DNA; 4.2.2.1 Requirements for Biosafe Plasmids; 4.2.2.2 Positive Impact on the Removal of Antibiotic Resistance Markers. | |
| 505 | 8 | _a4.2.2.3 Effect of Plasmid Size on Gene Transfer Efficiency In Vitro and In Vivo4.3 Nonviral Gene Vectors Devoid of Antibiotic Resistance Markers; 4.3.1 Generalities; 4.3.2 Selection Systems Devoid of Antibiotic Resistance Markers; 4.3.2.1 Complementation of Host Auxotrophy by a Function-Encoded Plasmid; 4.3.2.2 The Operator-Repressor Titration (ORT) System; 4.3.2.3 Protein-Based Antidote/Poison Selection Systems; 4.3.2.4 RNA-Based Selection Marker; 4.3.2.5 Suppression of a Nonsense Mutation; 4.4 The pFAR Plasmid Family; 4.4.1 Description of the Antibiotic-Free Selection System. | |
| 505 | 8 | _a4.4.2 pFAR Vectors Promote Efficient Expression in Several Types of Mammalian Cells4.4.2.1 In Vitro Transfection Study; 4.4.2.2 In Vivo Transfection Studies; 4.4.3 Concluding Remarks on the pFAR4 Biosafe Miniplasmid; 4.5 Concluding Remarks and Perspectives; Acknowledgments; References; 5 Plasmid DNA Concatemers: Influence of Plasmid Structure on Transfection Efficiency; 5.1 Introduction; 5.2 Plasmid DNA Topology and Size; 5.3 Plasmid DNA Concatemers; 5.4 Conclusions; Acknowledgments; References; 6 Analytical Tools in Minicircle Production; 6.1 Introduction. | |
| 520 | _aThis first title on the topic provides complete coverage, including the molecular basis, production and possible biomedical applications. Written by the most prominent academic researchers in the field as well as by researchers at one of the world's leading companies in industrial production of minicircle DNA, this practical book is aimed at everyone who is directly or indirectly involved in the development of gene therapies. | ||
| 650 | 0 |
_aPlasmids _xGenetics. |
|
| 650 | 0 | _aGenetic engineering. | |
| 650 | 2 | _aPlasmids. | |
| 650 | 4 | _aGene therapy. | |
| 650 | 4 | _aGenetic engineering. | |
| 650 | 4 |
_aPlasmids _xGenetics. |
|
| 650 | 7 |
_aNATURE _xPlants _xMushrooms. _2bisacsh |
|
| 650 | 7 |
_aGenetic engineering. _2fast _0(OCoLC)fst00940027 |
|
| 650 | 7 |
_aPlasmids _xGenetics. _2fast _0(OCoLC)fst01066381 |
|
| 655 | 4 | _aElectronic books. | |
| 655 | 7 |
_aElectronic books. _2local |
|
| 700 | 1 |
_aSchleef, M. _q(Martin) |
|
| 776 | 0 | 8 |
_iPrint version: _tMinicircle and miniplasmid DNA vectors. _dWeinheim, Germany : Wiley-Blackwell, ©2013 _z9783527324569 |
| 856 | 4 | 0 |
_uhttp://dx.doi.org/10.1002/9783527670420 _zWiley Online Library |
| 994 |
_a92 _bDG1 |
||
| 999 |
_c20260 _d20219 |
||